ERA - Leading European Nephrology

My ERA Join ERA

Home | Video pages | Webcast | Efficacy and Safety of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Patients with Chronic Kidney Disease

Efficacy and Safety of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Patients with Chronic Kidney Disease

Share

https://www.youtube.com/watch?v=fBs4J41-LDE copy

Access paper

Efficacy and Safety of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Patients with Chronic Kidney Disease

Other e-seminars from this series

Using Artificial Intelligence to Predict Mortality in AKI Patients: A systematic review/Meta-Analysis

ERA Journal Club

Clinical impact of the Kidney Failure Risk Equation for vascular access planning

ERA Journal Club

Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological malignancies

ERA Journal Club

Patient dynamics, suspensions, transplantation and deaths in the Australian kidney transplant waitlist

ERA Journal Club

Monoclonal gammopathy of unknown significance in kidney transplanted patients

ERA Journal Club

All-cause and immune checkpoint inhibitor-associated acute kidney injury in immune checkpoint inhibitors users

ERA Journal Club

Age and time-dependent increase in incident anti-glomerular basement membrane disease

ERA Journal Club

Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease

ERA Journal Club

The association between dual RAAS inhibition and risk of AKI and hyperkalemia in patients with DKD

ERA Journal Club

Women’s representation in clinical trials of patients with chronic kidney disease

ERA Journal Club

Nonsteroidal mineralocorticoid receptor antagonists and cardiorenal outcomes in chronic kidney disease

ERA Journal Club

Direct oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation and CKD G3-G5D

ERA Journal Club